Completed PHASE1 INTERVENTIONAL 2-arm NCT01559077

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers

Sponsor: Alnylam Pharmaceuticals

Conditions TTR-mediated Amyloidosis

Interventions ALN-TTR02 Sterile Normal Saline (0.9% NaCl)

Updated 5 times since 2017 Last updated: Jan 14, 2013 Started: Mar 31, 2012 Primary completion: Jun 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on TTR-mediated Amyloidosis, this trial is completed. The trial is conducted by Alnylam Pharmaceuticals and has accumulated 5 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alnylam Pharmaceuticals

Data source: Alnylam Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom
• London, United Kingdom